Patent Office to Review a Regimen of AbbVie's Humira

Federal regulators agreed to review a key patent for Humira, sending shares of the anti-inflammatory drug’s maker, AbbVie, lower while lifting those of hopeful rival Coherus BioSciences.

from WSJ.com: US Business http://ift.tt/1OCzp8x
via IFTTT